CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss) Change in cumulative translation adjustment	Accumulated Other Comprehensive Income (Loss)	Equity of Non-controlling Interest	Change in cumulative translation adjustment	Total
Stockholders' equity, Beginning balance at Jan. 30, 2021	$ 130	$ 474,375	$ (447,455)					$ 27,050
Common Stock, Shares, Outstanding period beginning at Jan. 30, 2021	13,019,061
Net loss			(3,228)			$ (150)		(3,378)
Common stock issuances pursuant to equity compensation awards	$ 1	(262)						(261)
Common stock issuances pursuant to equity compensation awards (in shares)	76,341
Share-based payment compensation		668						668
Common stock and warrant issuance	$ 33	21,191						21,224
Common stock and warrant issuance (in shares)	3,289,000
Investment of non-controlling interest						3,430		3,430
Stockholders' equity, ending balance at May. 01, 2021	$ 164	495,972	(450,683)			3,280		48,733
Common Stock, Shares, Outstanding period end at May. 01, 2021	16,384,402
Net loss			(4,249)			(132)		(4,381)
Common stock issuances pursuant to equity compensation awards (in shares)	39,094
Share-based payment compensation		768						768
Common stock and warrant issuance	$ 48	40,095						40,143
Common stock and warrant issuance (in shares)	4,830,918
Stockholders' equity, ending balance at Jul. 31, 2021	$ 212	536,835	(454,932)			3,148		85,263
Common Stock, Shares, Outstanding period end at Jul. 31, 2021	21,254,414
Stockholders' equity, Beginning balance at Jan. 29, 2022	$ 216	538,627	(469,463)		$ (2,428)	2,412		$ 69,363
Common Stock, Shares, Outstanding period beginning at Jan. 29, 2022	21,571,387							21,571,387
Net loss			(11,896)			(319)		$ (12,215)
Common stock issuances pursuant to equity compensation awards	$ 2	(212)						(210)
Common stock issuances pursuant to equity compensation awards (in shares)	232,630
Share-based payment compensation		985						985
Stockholders' equity, ending balance at Apr. 30, 2022	$ 218	539,400	(481,359)	$ (4,275)	(6,703)	2,093	$ (4,275)	53,649
Common Stock, Shares, Outstanding period end at Apr. 30, 2022	21,804,017
Net loss			(12,691)			(96)		(12,787)
Common stock issuances pursuant to equity compensation awards	$ 2	(13)						(11)
Common stock issuances pursuant to equity compensation awards (in shares)	177,550
Share-based payment compensation		1,123						1,123
Divestiture of Business						$ (1,997)		(1,997)
Common stock and warrant issuance	$ 35	18,438						18,473
Common stock and warrant issuance (in shares)	3,500,822
Stockholders' equity, ending balance at Jul. 30, 2022	$ 255	$ 558,948	$ (494,050)	$ (3,401)	$ (10,104)		$ (3,401)	$ 55,049
Common Stock, Shares, Outstanding period end at Jul. 30, 2022	25,482,389							25,482,389